These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33068250)

  • 21. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
    Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
    Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-Related Quality of Life Outcomes in PARADIGM-HF.
    Lewis EF; Claggett BL; McMurray JJV; Packer M; Lefkowitz MP; Rouleau JL; Liu J; Shi VC; Zile MR; Desai AS; Solomon SD; Swedberg K
    Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28784687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.
    Briasoulis A; Kuno T; Ueyama H
    Am J Cardiol; 2021 Aug; 153():150-152. PubMed ID: 34210504
    [No Abstract]   [Full Text] [Related]  

  • 25. Sacubitril-Valsartan in a routine community population: attention to volume status critical to achieving target dose.
    Pharithi RB; Ferre-Vallverdu M; Maisel AS; O'Connell E; Walshe M; Sweeney C; Barton J; McDonald K; O'Hare D; Watson C; Gallagher J; Ledwidge M; McDonald K
    ESC Heart Fail; 2020 Feb; 7(1):158-166. PubMed ID: 31903729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study.
    Senni M; Wachter R; Witte KK; Straburzynska-Migaj E; Belohlavek J; Fonseca C; Mueller C; Lonn E; Chakrabarti A; Bao W; Noe A; Schwende H; Butylin D; Pascual-Figal D;
    Eur J Heart Fail; 2020 Feb; 22(2):303-312. PubMed ID: 31820537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data.
    Gagne JJ; Tsacogianis T; Bruce Wirta S; Rogers JR; Calado F; Chang CL; Turner SJ; Schlienger RG; Balas B; Abdurrob A; Najafzadeh M; Wang SV
    J Comp Eff Res; 2018 Nov; 7(11):1073-1082. PubMed ID: 30156128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
    Packer M; Claggett B; Lefkowitz MP; McMurray JJV; Rouleau JL; Solomon SD; Zile MR
    Lancet Diabetes Endocrinol; 2018 Jul; 6(7):547-554. PubMed ID: 29661699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
    Marques da Silva P; Aguiar C
    Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
    Chandra A; Lewis EF; Claggett BL; Desai AS; Packer M; Zile MR; Swedberg K; Rouleau JL; Shi VC; Lefkowitz MP; Katova T; McMurray JJV; Solomon SD
    JAMA Cardiol; 2018 Jun; 3(6):498-505. PubMed ID: 29617523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
    McMurray JJV; Jackson AM; Lam CSP; Redfield MM; Anand IS; Ge J; Lefkowitz MP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Rizkala AR; Sabarwal SV; Shah AM; Shah SJ; Shi VC; van Veldhuisen DJ; Zannad F; Zile MR; Cikes M; Goncalvesova E; Katova T; Kosztin A; Lelonek M; Sweitzer N; Vardeny O; Claggett B; Jhund PS; Solomon SD
    Circulation; 2020 Feb; 141(5):338-351. PubMed ID: 31736337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
    Florea VG; Rector TS; Anand IS; Cohn JN
    Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
    Berg DD; Braunwald E; DeVore AD; Lala A; Pinney SP; Duffy CI; Gurmu Y; Velazquez EJ; Morrow DA
    JACC Heart Fail; 2020 Oct; 8(10):834-843. PubMed ID: 32800511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In brief: Sacubitril/valsartan (Entresto) expanded indication.
    Med Lett Drugs Ther; 2021 May; 63(1623):65. PubMed ID: 33976096
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.